



# Schizophrenia International Research Society

**PRESIDENT**

René S. Kahn, M.D., Ph.D.

**PRESIDENT-ELECT**

Patrick McGorry, FRCP, M.D.,  
Ph.D.

**PAST PRESIDENT**

John Kane, M.D.

**SECRETARY**

Cynthia Shannon Weickert, M.D.

**TREASURER**

Til Wykes, Ph. D.

**BOARD OF DIRECTORS**

Celso Arango, M.D., Ph.D.  
Anissa Abi-Dargham, M.D.  
Herbert Y. Meltzer, M.D.  
Michael Green, Ph.D.  
Paola Dazzan, M.D., M.Sc., Ph.D.  
Stephan Heckers, M.D., M.Sc.  
Sophia Vinogradov, M.D.  
Tyrone Cannon, Ph.D.

**EXECUTIVE DIRECTOR**

Ronnie Wilkins, Ed.D., CAE

The Society recognises the important role that industry, including the pharmaceutical industry plays in schizophrenia research and treatment.

The Ethics Committee Chairs have drawn up the following principles to govern the relationship between SIRS and commercial organisations.

1. The membership of SIRS is open to all professionals and students, including those employed by commercial corporations provided they meet the criteria set out in the Society's rules. We would encourage applications for membership from industry representatives.
2. Attendance at SIRS scientific meetings is open to all those with a bona fide interest in schizophrenia research including those from commercial and non-commercial health and science sectors.
3. Submissions to conferences such as symposia, posters and oral presentations should clearly indicate that the author(s) are employees and affiliates of pharmaceutical and other companies, alongside the source of funding for the work presented. Any other relevant interests should be declared in accordance with existing disclosure rules of the Society.
4. Such submissions will be subject to the same peer-review as those from clinical and academic individuals and institutions to ensure quality and scientific rigour. Submissions which appear to have a significant marketing element will not be accepted.
5. Offers of sponsorship or other relationships between commercial entities and corporations and SIRS will be decided upon by the officers of the Society on the basis of the SIRS mission and the wider interests of the Society (this may include sponsored symposia, exhibits, etc).

The ethical principles which should guide such relationships include:

- The need to consider at all time the best interests of schizophrenia patients and their families.
- The need to foster and nurture quality scientific efforts in relation to schizophrenia and related disorders around the world.
- A commitment to work with SIRS to minimise any conflicts of interest, ensure integrity, and uphold ethical practices in all aspects of the SIRS-Industry relationship.

**Executive Office**

[info@schizophreniaresearchsociety.org](mailto:info@schizophreniaresearchsociety.org)  
5034A Thoroughbred Lane  
Brentwood, Tennessee 37027 USA  
Tel: +1 615 324 2370  
Fax: +1 615 523 1715  
[www.schizophreniaresearchsociety.org](http://www.schizophreniaresearchsociety.org)